Thermo Fisher Scientific Inc.

Equities

TMO

US8835561023

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 04:00:02 2024-12-03 pm EST			5-day change	1st Jan Change
534.42 ^USD	+0.84%		+4.18%	+0.68%

Dec. 02	Nephron Research Trims Price Target on Thermo Fisher Scientific to $650 From $675	MT
Nov. 21	CMB International Initiates Thermo Fisher Scientific at Buy With $670 Price Target	MT

Thermo Fisher Scientific Inc. Declares Quarterly Cash Dividend, Payable on January 15, 2025

November 07, 2024 at 05:00 pm EST

Thermo Fisher Scientific Inc. announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on January 15, 2025, to shareholders of record as of December 13, 2024.

Latest news about Thermo Fisher Scientific Inc.

Nephron Research Trims Price Target on Thermo Fisher Scientific to $650 From $675	Dec. 02	MT
CMB International Initiates Thermo Fisher Scientific at Buy With $670 Price Target	Nov. 21	MT
Thermo Fisher Scientific Inc. Presents at 6th Annual Wolfe Research Healthcare Conference 2024, Nov-19-2024 08:00 AM	Nov. 19
Thermo Fisher Scientific Authorizes $4 Billion Share Buyback	Nov. 15	MT
Thermo Fisher Board Approves New $4 Billion Stock Buyback	Nov. 15	DJ
Tranche Update on Thermo Fisher Scientific Inc.'s Equity Buyback Plan announced on November 14, 2023.	Nov. 15	CI
Thermo Fisher Scientific Inc. announces an Equity Buyback for $4,000 million worth of its shares.	Nov. 15	CI
Thermo Fisher Scientific Inc.'s Equity Buyback announced on November 14, 2023, has expired with 5,523,139 shares, representing 1.43% for $3,000 million.	Nov. 14	CI
Thermo Fisher Scientific Inc. authorizes a Buyback Plan.	Nov. 14	CI
Mainz Biomed, Thermo Fisher Partner to Develop Colorectal Cancer Screening Test	Nov. 12	MT
Mainz Biomed N.V. and Thermo Fisher Scientific Inc. Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets	Nov. 12	CI
Quidelortho Corporation Announces Executive Changes	Nov. 08	CI
Seer Enters into A Co-Marketing and Sales Agreement with Thermo Fisher Scientific	Nov. 06	CI
Tranche Update on Thermo Fisher Scientific Inc.'s Equity Buyback Plan announced on November 14, 2023.	Nov. 01	CI
Thermo Fisher Scientific Insider Sold Shares Worth $11,049,123, According to a Recent SEC Filing	Oct. 30	MT
Thermo Fisher Scientific Insider Sold Shares Worth $1,120,320, According to a Recent SEC Filing	Oct. 29	MT
Devyser Enters Collaboration to Secure US Approval for Kidney Transplant Monitoring Test	Oct. 29	MT
Devyser aims to secure FDA approval for monitoring product	Oct. 29	FW
Devyser Enters into Agreement with Thermo Fisher Scientific to Collaborate on Obtaining U.S. Food and Drug Administration Approval for One Lambda? Devyser Accept Cfdna	Oct. 29	CI
ARC Independent Upgrades Thermo Fisher Scientific to Buy From Hold, $620 Price Target	Oct. 28	MT
Stephens Adjusts Price Target on Thermo Fisher Scientific to $670 From $680, Maintains Overweight Rating	Oct. 25	MT
Redburn Atlantic Adjusts Price Target on Thermo Fisher Scientific to $645 From $680	Oct. 25	MT
Morgan Stanley Adjusts Price Target on Thermo Fisher Scientific to $670 From $680, Maintains Overweight Rating	Oct. 24	MT
Bernstein Adjusts Price Target on Thermo Fisher Scientific to $620 From $625, Maintains Market Perform Rating	Oct. 24	MT
Raymond James Adjusts Price Target on Thermo Fisher Scientific to $650 From $660, Maintains Outperform Rating	Oct. 24	MT

Chart Thermo Fisher Scientific Inc.

Duration

Period

TMO: Dynamic Chart

Company Profile

Thermo Fisher Scientific Inc. specializes in the design, manufacturing and marketing of laboratory and scientific equipments. Net sales (including intragroup) break down by family of products as follows: - laboratory equipments (70%). Moreover, the group proposes chemical products (reagents, solvent, salts, etc.), consumable products (tubes, funnels, vials, etc.), as well as conditioning, warehousing, storage, etc.; - diagnostics equipment and products (15.3%); - scientific analysis equipments (14.7%): analyzer (of water, gas, grounds, etc.), mass spectrometers, molecular spectroscopes, microscopes, manometers, samplers, microbiology equipments, reactive agents, etc. Net sales break down by source of income into products sales (78.5%) and services (21.5%). Net sales break down geographically as follows: North America (53%), Europe (25.7%), Asia-Pacific (18.1%) and others (3.2%).

Employees

122,000

Sector

Advanced Medical Equipment & Technology

Calendar

2024-12-12 - Détachement de

More about the company